Abstract
Tumor cells are essentially identical to the normal cells of the host in view of biochemical or molecular biological events and machineries thereof. However, I see a great difference between tumor and normal cells exists at the tissue level, particularly in tumor blood vessels. Therefore, it is a wise choice to develop a drug which will seek and find this unique character at the vascular level[1]. Macromolecules with biocompatible nature can be best utilized in this respect since we found that they leak out at the tumor blood vessels more selectively and remain uncleared in the tumor tissues for long time: i.e. extravasation into interstitial tumor tissue is much enhanced, but the clearance from tumor is greatly suppressed compared to the normal tissues. I coined this phenomenon as enhanced permeability and retention (EPR) effect of macromolecules and lipids in solid tumor[2–5].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46: 6387–6392
Maeda H (1991) SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv. Drug Delivery Review 6: 181–202
Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principle of macromolecular drug. Crit. Rev. Ther. Drug Carrier Syst. 6: 193–210
Maeda H, Seymour L W, Miyamoto Y (1992) Conjugation of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconj. Chem. 3: 351–362
Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M (1984) Tailor-making of protein drugs by polymer-conjugation for tumor targeting: A brief reveiw on smancs. J. Protein Chem. 3: 181–193
Maeda H, Oda T, Matsumura Y. Kimura M (1988) Improved pharmacological properties of protein-drugs by tailoring with synthetic polymers. J. Bioactive Compatible Polymers 3: 27–43
Yamaoka T, Tabata Y, Ikada Y (1994) Accumulation of polyvinylalcohol at inflammatory site. In: Polymeric Drugs and Drug Administration. R.M. Ottenbrite (ed.) Am. Chem. Soc, pp 163–171
Duncan R (1992) Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drug 3: 195–210
Tsutsumi Y, Kihara T, Yamamoto S, Kubo K, Nakagawa S, Miyake M, Horisawa Y, Kanamori T, Ikegarni H, Mayumi T (1994) Chemical modification of natural human tumor necrosis factor a with polyethylene glycol increased its antitumor potency. Jpn. J. Cancer Res. 5: 9–12
Katre NV, Knauf MJ, Laird WJ (1987) Chemical modification of recombinant interleukin 2 by polyethytlene glycol increases its potency in murine Meth A sarcoma model. Proc. Nat. Acad. Sci. 84: 1487–1491
Iwai K, Maeda H, Konno T (1984) Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and X-ray image. Cancer Res., 44: 2115–2121
Suzuki F, Pollard RB, Maeda H (1989) Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic acid-styrene)-conjugated neocarzinostatin. Cancer Immunol. Immunother., 30:97–104
Oda T, Morinaga T, Maeda H (1986) Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc. Soc. Exp. Biol. Med. 181: 9–17
Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M, Miyauchi Y (1984) Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54: 2367–2374
Kobayashi M, Maeda H, Imai K, Konno T, Sugihara S, Yamanaka H (1991) Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma. Urology 37: 288–294
Kimura M, Konno T, Oda T, Maeda H, Miyauchi Y (1993) Intracavitary treatment of malignant ascitic carcinomatosis with oily anticancer agents in rats. Anticancer Res. 13: 1287–1292
Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, Duncan R (1995) Influence of molecular weight on passive tumor accumulation of soluble macromolecular drug carrier. Eur. J. Cancer (May, in press)
Li CJ, Miyamoto Y, Kojima Y, Maeda H (1993) Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 67: 975–980
Maeda H, Miyamoto Y (1994) SMANCS approach — Oily formulations of protein drug for arterial injection and oral administration. In: Drug Absorption Enhancement. H.G.de Boer (ed) Harwood Academic Pubis, pp 221–247
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Tokyo
About this paper
Cite this paper
Maeda, H. (1996). Third Phase in Polymer Drug Development: — Smancs as a Prototype Model Drug for Cancer Treatment —. In: Ogata, N., Kim, S.W., Feijen, J., Okano, T. (eds) Advanced Biomaterials in Biomedical Engineering and Drug Delivery Systems. Springer, Tokyo. https://doi.org/10.1007/978-4-431-65883-2_20
Download citation
DOI: https://doi.org/10.1007/978-4-431-65883-2_20
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-65885-6
Online ISBN: 978-4-431-65883-2
eBook Packages: Springer Book Archive